1. Mycophenolate mofetil treatment for primary glomerular diseases
Michael J. Choi, Joseph A. Eustace, Luis F. Gimenez, Mohamed G. Atta, Paul J. Scheel, Renuka Sothinathan, William A. Briggs 
Kidney International 
Volume 61, Issue 3, Pages (March 2002)
DOI: /j x
Copyright © 2002 International Society of Nephrology Terms and Conditions

2. Figure 1
Median plus interquartile range of urine protein-to-creatine ratio (Up/c), serum albumin, and serum cholesterol and estimated glomerular filtration rate (GFR). (A) Median plus interquartile range, pre- and post-mycophenolate mofetil (MMF) treatment, of the Up/c ratio is shown for the entire study population. (B) Median plus interquartile range of serum albumin prior to and after MMF treatment of the overall group is demonstrated. (C) Median plus interquartile range pre- and post-MMF treatment serum cholesterol for the overall group is shown. (D) Median plus interquartile range pre- and post-treatment GFR as estimated by the modified four-variable MDRD equation.
Kidney International  , DOI: ( /j x)
Copyright © 2002 International Society of Nephrology Terms and Conditions

3. Figure 2
Up/c at initiation and at the end of the MMF treatment period in individual nephrotic FSGS patients. # is the patient identification number in Table 1. mo = months of MMF therapy.
Kidney International  , DOI: ( /j x)
Copyright © 2002 International Society of Nephrology Terms and Conditions

4. Figure 3
Up/c at initiation and at the end of MMF treatment in individual nephrotic membranous nephropathy patients. # is the patient identification number in Table 1. mo = months of MMF therapy.
Kidney International  , DOI: ( /j x)
Copyright © 2002 International Society of Nephrology Terms and Conditions

5. Figure 4
Patients with rapidly rising serum creatinine. Eight patients demonstrated a ≥20% increase in the serum creatinine 40 weeks prior to MMF therapy. The serum creatinines of these 8 patients are shown prior to and after MMF therapy started.
Kidney International  , DOI: ( /j x)
Copyright © 2002 International Society of Nephrology Terms and Conditions